ARTICLE | Clinical News
CAT-152: Complete Phase II study
February 5, 2001 8:00 AM UTC
Cambridge Antibody Technology Group plc (LSE:CAT), Melbourn, U.K. Product: CAT-152 Business: Ophthalmic Therapeutic category: Antibody, Cell proliferation Target: TGFbeta-2 Description: Human monoclon...